Russian registry of Infliximab.Impact of therapy on the functional status of patients with rheumatoid arthritis

Objective. To evaluate the functional state of rheumatoid arthritis (RA) patients receiving Infliximab therapy (IF) in real clinical practice and its efficiency. Subjects and methods. The analysis covered 225 patients receiving IF therapy, the follow-up duration in whom was 54 weeks. Disease activit...

Full description

Saved in:
Bibliographic Details
Main Authors: V N Amirdzhanova, Elena Yur'evna Kaygorodtseva, D V Goryachev, G V Lukina, E S Pozdnyakova, Ya A Sigidin, E L Nasonov, Elena Yuryevna Kaigorodtseva
Format: Article
Language:Russian
Published: IMA PRESS LLC 2010-12-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/952
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849688957359489024
author V N Amirdzhanova
Elena Yur'evna Kaygorodtseva
D V Goryachev
G V Lukina
E S Pozdnyakova
Ya A Sigidin
E L Nasonov
V N Amirdzhanova
Elena Yuryevna Kaigorodtseva
D V Goryachev
G V Lukina
E S Pozdnyakova
Ya A Sigidin
E L Nasonov
author_facet V N Amirdzhanova
Elena Yur'evna Kaygorodtseva
D V Goryachev
G V Lukina
E S Pozdnyakova
Ya A Sigidin
E L Nasonov
V N Amirdzhanova
Elena Yuryevna Kaigorodtseva
D V Goryachev
G V Lukina
E S Pozdnyakova
Ya A Sigidin
E L Nasonov
author_sort V N Amirdzhanova
collection DOAJ
description Objective. To evaluate the functional state of rheumatoid arthritis (RA) patients receiving Infliximab therapy (IF) in real clinical practice and its efficiency. Subjects and methods. The analysis covered 225 patients receiving IF therapy, the follow-up duration in whom was 54 weeks. Disease activity was estimated by the DAS 28 index; functional status was assessed according to the Health Assessment Questionnaire (HAQ). The authors made an analysis of a Per-Protocol (PP) population (n = 154) at 54 weeks of treatment and an analysis that could consider the results of treatment (by the ACR and EULAR criteria) in patients who had been withdrawn before the control time - a LOCF (Last Observation Carried Forward analysis) population. Results. The mean age of the patients was 47.6±11.4 years; the duration of the disease was 7.8±6.4 years; DAS 28 activity scores were 6.6±1.1; the majority of patients had significant functional impairments (HAQ scores of 2.0±0.7), 86.7% of the patients had extraarticular manifestations; 79.6% were found to have rheumatoid factor (RF); the patients received an average of > 2 disease-modifying antirheumatic drugs (DMARDs). After 2 week-therapy, there was a reduction in RA activity by DAS 28 index in both the PP (from 6.7±1.1 to 4.0±1.4) and LOCF (6.6±1.1 and 4.2±1.4; p < 106) populations. Drug-induced remission (DAS 28 < 2.6) at 54 weeks was observed in 16.9 and 15.1% of the patients, respectively. Functional improvement was noted in the PP population: HAQ decreased from 2.0±0.7 to 1.7±0.7 scores by week 2; its reduction continued until week 14 (p < 0.05), by remaining stable later on. HAQ dropped from 2.0±0.7 to 1.2±0.7 scores in the LOCF population. At 54 weeks, normal population values of functional activity were achieved in 16.4%. Log regression analysis in the LOCF population indicated that the previous use of DMARDs and a short history of the disease were predictors of an ACR70 response to IF therapy [OR=1.61 (1.13-2.30), p = 0.008 and OR = 0.91 (0.84-0.98), p = 0.018, respectively]. RF seronegativity was a predictor for achievement of low RA activity [OR = 0.44 (0.23-0.84)]. The previous use of glucocorticoids failed to increase the probability of a good response to IF therapy and achievement of clinical remission [OR = 0.26 (0.11-0.60), p = 0.001]. Conclusion. Therapy with IF in combination with methotrexate or other DMARDs reduces RA activity and improves the functional capacities of patients with RA in real clinical practice.
format Article
id doaj-art-ee858b087b3a4d1a8d1e72d516fe5c4e
institution DOAJ
issn 1995-4484
1995-4492
language Russian
publishDate 2010-12-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj-art-ee858b087b3a4d1a8d1e72d516fe5c4e2025-08-20T03:21:47ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922010-12-01486233010.14412/1995-4484-2010-819892Russian registry of Infliximab.Impact of therapy on the functional status of patients with rheumatoid arthritisV N AmirdzhanovaElena Yur'evna KaygorodtsevaD V GoryachevG V LukinaE S PozdnyakovaYa A SigidinE L NasonovV N AmirdzhanovaElena Yuryevna KaigorodtsevaD V GoryachevG V LukinaE S PozdnyakovaYa A SigidinE L NasonovObjective. To evaluate the functional state of rheumatoid arthritis (RA) patients receiving Infliximab therapy (IF) in real clinical practice and its efficiency. Subjects and methods. The analysis covered 225 patients receiving IF therapy, the follow-up duration in whom was 54 weeks. Disease activity was estimated by the DAS 28 index; functional status was assessed according to the Health Assessment Questionnaire (HAQ). The authors made an analysis of a Per-Protocol (PP) population (n = 154) at 54 weeks of treatment and an analysis that could consider the results of treatment (by the ACR and EULAR criteria) in patients who had been withdrawn before the control time - a LOCF (Last Observation Carried Forward analysis) population. Results. The mean age of the patients was 47.6±11.4 years; the duration of the disease was 7.8±6.4 years; DAS 28 activity scores were 6.6±1.1; the majority of patients had significant functional impairments (HAQ scores of 2.0±0.7), 86.7% of the patients had extraarticular manifestations; 79.6% were found to have rheumatoid factor (RF); the patients received an average of > 2 disease-modifying antirheumatic drugs (DMARDs). After 2 week-therapy, there was a reduction in RA activity by DAS 28 index in both the PP (from 6.7±1.1 to 4.0±1.4) and LOCF (6.6±1.1 and 4.2±1.4; p < 106) populations. Drug-induced remission (DAS 28 < 2.6) at 54 weeks was observed in 16.9 and 15.1% of the patients, respectively. Functional improvement was noted in the PP population: HAQ decreased from 2.0±0.7 to 1.7±0.7 scores by week 2; its reduction continued until week 14 (p < 0.05), by remaining stable later on. HAQ dropped from 2.0±0.7 to 1.2±0.7 scores in the LOCF population. At 54 weeks, normal population values of functional activity were achieved in 16.4%. Log regression analysis in the LOCF population indicated that the previous use of DMARDs and a short history of the disease were predictors of an ACR70 response to IF therapy [OR=1.61 (1.13-2.30), p = 0.008 and OR = 0.91 (0.84-0.98), p = 0.018, respectively]. RF seronegativity was a predictor for achievement of low RA activity [OR = 0.44 (0.23-0.84)]. The previous use of glucocorticoids failed to increase the probability of a good response to IF therapy and achievement of clinical remission [OR = 0.26 (0.11-0.60), p = 0.001]. Conclusion. Therapy with IF in combination with methotrexate or other DMARDs reduces RA activity and improves the functional capacities of patients with RA in real clinical practice.https://rsp.mediar-press.net/rsp/article/view/952infliximabpatients' functional stateregistry of infliximab
spellingShingle V N Amirdzhanova
Elena Yur'evna Kaygorodtseva
D V Goryachev
G V Lukina
E S Pozdnyakova
Ya A Sigidin
E L Nasonov
V N Amirdzhanova
Elena Yuryevna Kaigorodtseva
D V Goryachev
G V Lukina
E S Pozdnyakova
Ya A Sigidin
E L Nasonov
Russian registry of Infliximab.Impact of therapy on the functional status of patients with rheumatoid arthritis
Научно-практическая ревматология
infliximab
patients' functional state
registry of infliximab
title Russian registry of Infliximab.Impact of therapy on the functional status of patients with rheumatoid arthritis
title_full Russian registry of Infliximab.Impact of therapy on the functional status of patients with rheumatoid arthritis
title_fullStr Russian registry of Infliximab.Impact of therapy on the functional status of patients with rheumatoid arthritis
title_full_unstemmed Russian registry of Infliximab.Impact of therapy on the functional status of patients with rheumatoid arthritis
title_short Russian registry of Infliximab.Impact of therapy on the functional status of patients with rheumatoid arthritis
title_sort russian registry of infliximab impact of therapy on the functional status of patients with rheumatoid arthritis
topic infliximab
patients' functional state
registry of infliximab
url https://rsp.mediar-press.net/rsp/article/view/952
work_keys_str_mv AT vnamirdzhanova russianregistryofinfliximabimpactoftherapyonthefunctionalstatusofpatientswithrheumatoidarthritis
AT elenayurevnakaygorodtseva russianregistryofinfliximabimpactoftherapyonthefunctionalstatusofpatientswithrheumatoidarthritis
AT dvgoryachev russianregistryofinfliximabimpactoftherapyonthefunctionalstatusofpatientswithrheumatoidarthritis
AT gvlukina russianregistryofinfliximabimpactoftherapyonthefunctionalstatusofpatientswithrheumatoidarthritis
AT espozdnyakova russianregistryofinfliximabimpactoftherapyonthefunctionalstatusofpatientswithrheumatoidarthritis
AT yaasigidin russianregistryofinfliximabimpactoftherapyonthefunctionalstatusofpatientswithrheumatoidarthritis
AT elnasonov russianregistryofinfliximabimpactoftherapyonthefunctionalstatusofpatientswithrheumatoidarthritis
AT vnamirdzhanova russianregistryofinfliximabimpactoftherapyonthefunctionalstatusofpatientswithrheumatoidarthritis
AT elenayuryevnakaigorodtseva russianregistryofinfliximabimpactoftherapyonthefunctionalstatusofpatientswithrheumatoidarthritis
AT dvgoryachev russianregistryofinfliximabimpactoftherapyonthefunctionalstatusofpatientswithrheumatoidarthritis
AT gvlukina russianregistryofinfliximabimpactoftherapyonthefunctionalstatusofpatientswithrheumatoidarthritis
AT espozdnyakova russianregistryofinfliximabimpactoftherapyonthefunctionalstatusofpatientswithrheumatoidarthritis
AT yaasigidin russianregistryofinfliximabimpactoftherapyonthefunctionalstatusofpatientswithrheumatoidarthritis
AT elnasonov russianregistryofinfliximabimpactoftherapyonthefunctionalstatusofpatientswithrheumatoidarthritis